The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma

Cough Variant Asthma Clinical Trial

Official title:

Randomised, Open-label, Parallel-group Study of the Response to Bronchodilator Treatment in Subjects With Eosinophilic Bronchitis and the Mechanism of Varied Responses to Bronchodilator Treatment.

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT02002754
• Other study ID #: cough2009
• Status: Unknown status
• Phase: Phase 4
• First received: December 2, 2013
• Last updated: December 5, 2013
• Start date: June 2012
• Est. completion date: March 2014

Study information

• Verified date: December 2013
• Source: The First Affiliated Hospital of Guangzhou Medical University
• Contact: Lai Kefang, PhD
• Phone: 8620 83062893
• Email: kelai[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aim is to observe the response to Bambuterol Hydrochloride tablets treatment in subjects with eosinophilic bronchitis .

The investigators hypothesize:

A few of subjects with EB have some responses to Bambuterol Hydrochloride tablets therapy.

Most of subjects with CVA respond well to Bambuterol Hydrochloride tablets therapy

Description:

Study groups:

45 patients with chronic cough will be collected and two groups will formed based on diagnosis as follows:

Group 1: EB group The patients with eosinophilic bronchitis received Bambuterol Hydrochloride tablets 10mg Q24 for three days .

Group 2: CVA group The patients with cough variant asthma received Bambuterol Hydrochloride tablets 10mg Q24 for three days .

Observe the response to Bambuterol Hydrochloride tablets treatment three days later and compare the effective rate of patients with EB and CVA. Then the study will be over.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 45
• Est. completion date: March 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients who have a history of cough as sole or main symptom lasting more than 8 weeks.

2. Patients whose chest x-ray outcome was normal or without any active focus.

3. Patients with eosinophilic bronchitis who were diagnosed with the result of sputum eosinophil percentage (Eos%) over 2.5%, and the negative result in bronchial provocation test by methacholine inhalation challenge.

4. Patients with cough variant asthma have positive result in bronchial provocation test.

5. Patients who was aged from 18 years old (= 18 years old ) to 75 years old (= 75 years old).

Exclusion Criteria:

1. Patients who is a smoker or ex-smoker and has smoked within the previous year or has a cumulative smoking history >10 pack-years or equivalence.

2. Patients with concomitance of GERC (gastroesophageal reflux-related chronic cough), chronic bronchitis , bronchiectasis, bronchial tuberculosis, ACEI induced cough, bronchogenic carcinoma, psychologic cough, pulmonary fibrosis, bronchus foreign body, microlithiasis, tracheobroncheopathia osteochondroplastica, mediastinal tumor, left ventricular dysfunction.

3. Female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study.

4. Subjects who are diagnosed with past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease. e.g.nasal-sinus infection, lower respiratory tract infection, chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis or bronchopulmonary dysplasia.

5. Subjects who demonstrate significant abnormality on biochemistry, hematology, ECG.

6. Patients who does not cooperate with us.

Related Conditions & MeSH terms

• Acute Disease
• Asthma
• Bronchitis
• Cough
• Cough Variant Asthma
• Eosinophilic Bronchitis

Intervention

Drug:
• Bambuterol Hydrochloride tablets
Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)

Locations

Country	Name	City	State
China	Guangzhou Institute of Respiratory Disease	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Guangzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Day-time and night-time cough symptom total-score changes from baseline to day 3.		three days
Secondary	cough sensitivity from baseline to day 3		three days